On August 15, the US Food and Drug Administration (FDA) approved durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

For more information read the FDA announcement and the AstraZeneca announcement.

Posted on 8/21/2024